Activity Summary:
Adult HLH is increasingly recognized as part of a broader hyperinflammatory spectrum, yet early diagnosis and management remain challenging in clinical practice. Because many adults present with nonspecific symptoms that overlap with sepsis, malignancy-associated inflammation, or autoimmune disease, timely recognition and treatment can be difficult.

This four-episode podcast series explores the full spectrum of adult HLH, from raising diagnostic suspicion to implementing contemporary treatment strategies. Through expert discussion and real-world clinical insights, Dr. Sarah Nikiforow and Dr. Daniella Schwartz aim to strengthen the ability to recognize HLH across diverse clinical settings, integrate biomarkers and prognostic indicators into clinical decision-making, and apply adult-specific management strategies, including emerging therapeutic options.

Activity Summary:
Adult HLH is increasingly recognized as part of a broader hyperinflammatory spectrum, yet early identification and management remain challenging in routine clinical practice. Many adult patients present with nonspecific symptoms that overlap with sepsis, malignancy-associated inflammation, or autoimmune disease, which can delay recognition and treatment.

In this series, Drs. Sarah Nikiforow and Daniella Schwartz explore the full spectrum of adult HLH, from diagnostic suspicion to modern treatment approaches. Through four episodes, this activity aims to strengthen the ability to recognize HLH across diverse clinical settings, integrate biomarkers and prognostic indicators into clinical decision-making, and apply adult-specific management strategies, including emerging therapeutic options.

Activity Summary:
To further build on the insights presented in the Clinical Clips® from EASL Congress 2026: Key Breakthroughs in the Treatment of PBC by Dr. Kris Kowdley, HCPs can access a range of downloadable resources designed to reinforce key concepts and support practical application in clinical care.

Available Resources:

Downloadable Slide Deck (PDF)
Downloadable version of the presentation slides used by the faculty, including data visuals, figures, and key discussion points.

Expert Commentary Transcript
A transcript of the podcast version of the program, reflecting the expert discussion and interpretation of EASL 2026 data.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
These podcast episodes explore the rapidly evolving treatment landscape of Primary Biliary Cholangitis, highlighting recent therapeutic advances and reviews emerging clinical evidence on promising investigational therapies.

Designed for healthcare professionals, these episodes provides expert commentary on the latest cutting-edge data presented at EASL Congress 2026. Through an engaging podcast format, listeners will gain practical insights into how new evidence can inform personalized treatment strategies, support improved patient outcomes, and enhance the overall quality of care for people living with PBC.

Activity Summary:
These videos provide a concise overview of the latest clinical developments in Primary Biliary Cholangitis presented at EASL Congress 2026. Expert faculty discuss emerging evidence that is shaping the evolving treatment landscape and what these updates may mean for clinical practice.

Watch to gain practical insights into applying the newest data to personalized patient management, with the goal of improving outcomes and advancing the quality of care for individuals living with PBC.

Activity Summary:
To further build on the insights presented in the Clinical Clips® in NF1-PN: Key Advances from AAN 2026 by Dr. Angela Hirbe, HCPs can access a range of downloadable resources designed to reinforce key concepts and support practical application in clinical care.

Available Resources:

Clinical Snippet Highlights: AAN 2026 Evidence at a Glance
A PDF summarizing each key presentation or poster featured in the Clinical Clip, with evidence-based takeaways for each study.

Downloadable Slide Deck (PDF)
Downloadable version of the presentation slides used by the faculty, including data visuals, figures, and key discussion points.

Expert Commentary Transcript
A transcript of the podcast version of the program, reflecting the expert discussion and interpretation of AAN 2026 data.

Discussion Guide: Applying Emerging NF1 Evidence Across the Lifespan
A brief guide with reflective questions and prompts related to patient selection, interpretation of outcomes beyond imaging, and longitudinal management considerations.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
To further expand knowledge from the Advancing Myasthenia Gravis Care: Emerging Insights from AAN 2026 presented by Dr. James Howard Jr., HCPs can access a variety of downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Available Resources:

Clinical Snippet Highlights: AAN 2026 Evidence in Myasthenia Gravis
A summary highlighting each abstract, presentation, or poster discussed in the Clip, with key findings, clinical relevance, and practical takeaways.

Downloadable Slides
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Podcast Transcript
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

Diagnostic and Severity Assessment Quick Reference
A reference guide summarizing diagnostic considerations, testing options, and commonly used severity assessment tools discussed in the program.

Emerging Treatment Landscape Overview
An overview outlining emerging treatment strategies covered in the Clip, including mechanisms of action and potential clinical considerations.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Leveraging emerging evidence presented at AAN, Dr. Angela Hirbe provides a synthesis of key findings, highlight their relevance across pediatric and adult care, and frames practical considerations for patient assessment and longitudinal management.

Activity Summary:
Clinical care for myasthenia gravis is entering a period of meaningful progress, with growing opportunities to improve how the disease is diagnosed, assessed, and treated. Increased awareness of disease heterogeneity and the expanding use of standardized severity assessments are helping clinicians better define disease burden and guide management decisions.

In this 20-minute podcast episode, Dr. James Howard Jr. provides comprehensive coverage of key MG presentations, scientific symposia, posters, and abstracts presented at AAN 2026.

Activity Summary:
Neurofibromatosis type 1 (NF1) treatment is evolving rapidly, with new data emerging across clinical trials and real-world studies. For busy clinicians, the challenge is not access to information, but quickly understanding what is clinically meaningful and how it should influence care.

This Clinical Clip from AAN 2026 delivers a focused, expert-led review of emerging NF1-PN treatment data in just 10-minutes. Designed for real-world practice, this concise update highlights key findings, clarifies their clinical relevance, and provides practical insights to support patient selection and treatment decisions.

Watch the clip to stay current, sharpen your clinical thinking, and translate new evidence into action.

Activity Summary:
Myasthenia gravis care is advancing quickly, with new evidence shaping how clinicians approach disease assessment and treatment selection. At the same time, variability in presentation, delays in diagnosis, and uncertainty around integrating emerging therapies continue to create challenges in clinical practice. Clinicians need concise, practical education that translates evolving data into clear and actionable strategies that can be applied in real-world care.

This focused Clinical Clip from AAN 2026 features Dr James (Chip) Howard, a leading expert in myasthenia gravis, delivering a 20-minute update on the most clinically relevant advances presented in Chicago. Designed for efficiency and practical application, this program highlights how to incorporate emerging therapies into individualized treatment plans to support confident, evidence-based decision-making.

Activity Summary:
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this Clinical Clip activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder marked by reduced platelet counts, purpura, and bleeding episodes driven by antiplatelet autoantibodies. Diagnosis remains one of exclusion, requiring careful differentiation from other causes of thrombocytopenia. Advances in pediatric ITP treatment are ushering in an era of precision medicine, integrating novel immunomodulatory therapies and personalized treatment approaches to optimize patient care. Recent research has introduced targeted pharmacological agents that address immune dysregulation, refining treatment protocols to align with individual patient profiles. The evolving landscape of pediatric ITP care calls for a comprehensive, evidence-driven approach, combining established therapies with innovative strategies to enhance efficacy and long-term disease management.

In this lecture library, Dr. Cindy Neunert provides expert insights into emerging data on ITP pathophysiology, diagnosis, and treatment, equipping healthcare providers with the knowledge to translate new research into clinical practice and improve pediatric patient care.

Activity Summary:
Myasthenia Gravis (MG) has had significant advances, however critical gaps persist in optimizing care. Challenges include variability in diagnostic accuracy, particularly in seronegative cases, and a limited adoption of newer, more sensitive testing modalities. Additionally, the evolving treatment landscape—with emerging therapies such as complement inhibitors and FcRn antagonists—highlights the need for clinicians to stay informed about the latest evidence and integrate these options into personalized care strategies. Addressing these gaps is crucial to improving patient care, enhancing quality of life, and reducing the burden of long-term side effects associated with traditional treatments.

This special edition podcast series with Dr. Nicholas Silvestri enables healthcare providers to engage with evidence-based insights and practical guidance on MG management at their convenience. The podcast format is ideal for professionals to access while commuting, during breaks, or between patient appointments, providing targeted learning without disrupting their workflow.

Activity Summary:
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this podcast activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Activity Summary:
There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from EASL 2025 and describe their implications for clinical practice. 

Activity Summary:
There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from EASL 2025 and describe their implications for clinical practice. 

Activity Summary:
In this Clinical Clip, Dr. Nicholas Silvestri provides a concise and clinically relevant summary of the most important emerging data presented at AAN 2025 that impact the management of generalized Myasthenia Gravis (gMG).

Topics covered include pivotal updates from recent clinical trials—such as MINT (inebilizumab), ADAPT NXT (efgartigimod), and MycarinG (rozanolixizumab)—highlighting the safety, efficacy, and practical implications of emerging therapies across diverse MG subtypes. The activity also explores trends in real-world treatment patterns, therapeutic inertia among neurologists, and new diagnostic approaches including advanced serologic testing and AI-supported electrophysiologic tools. With a focus on individualized care, this activity equips healthcare professionals with key insights to help integrate new therapies and diagnostic innovations into practice, ultimately supporting timely, targeted, and patient-centered management of MG.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.

Activity Summary:
Vitiligo is a relatively common acquired pigmentation disorder. The therapeutic effect of all the treatment modalities varies considerably from individual to individual. As such, treatment must be individualized. Moreover, vitiligo can carry significant psychosocial impact. Healthcare providers play a crucial role in shaping patients' understanding of their condition, approach to treatment, and coping mechanisms. In this podcast series, Dr. Raj Chovatiya, along with his patient, will discuss ways to individualized treatment strategies and improve holistic care of patients with vitiligo.

Activity Summary:
This podcast series features engaging discussions between leading experts and their patients with primary biliary cholangitis (PBC). The patients share their insights and experiences with PBC, its treatment, and key learning experiences in their journeys with PBC. The activity will enable participants to understand the importance of listening to patient perspectives when designing individualized care pathways to alleviate symptoms and improve quality of life.

Activity Summary:
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at AASLD 2024. In these video Clips, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.